This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Current Discounted Rates End In:

  • 00
  • 00
  • 00
  • 00
Delivered as Hybrid Event from September 20-30, 2021
Live In-Person Experience Delivered September 20-23Boston Convention and Exhibition Center

Michael Verlander, D.Phil.
President at Proactive Quality Compliance, Inc.


Dr. Verlander is currently acting as an independent consultant supporting the pharmaceutical industry in the areas of product development and quality and regulatory compliance; he also serves as a member of USP’s Biologics Monographs-1 Peptides and Oligonucleotides Expert Committee, as well as their Glatiramer Acetate Expert Panel.  Prior to this, he gained extensive experience in the areas of quality assurance and regulatory affairs in contract manufacturing organizations specializing in peptide APIs, including:  the PolyPeptide Group [as President of PolyPeptide Laboratories San Diego (2009-2013), Global Director of Quality Assurance and Regulatory Affairs (2003-2009), and Executive Vice President, Quality Assurance and Regulatory Affairs and Co-founder, PolyPeptide Laboratories, Inc. (1996-2009)]; and Bachem California [as Vice President, Technical and Regulatory Affairs (1986-1996)].  He has also worked in the area of peptide research and development [as Director of Peptide Research and Peptide Production, Immunetech Pharmaceuticals (1985-1986); Research Director, BioResearch, Inc. (1978-1985); and as a member of the research faculty at the University of California, San Diego, Department of Chemistry (1972-1978)]. 

Dr. Verlander received his undergraduate and graduate training in organic chemistry at the University of Oxford and his postdoctoral training at the Salk Institute for Biological Studies, La Jolla, California.  He has authored more than 50 peer-reviewed scientific papers and numerous patents on peptides and related topics.

Agenda Sessions

  • Quality Strategies for Peptide Development